Cargando…

Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice

BACKGROUND: Immune responses, both cellular and humoral, against cytomegalovirus (CMV) are used to predict CMV manifestations in solid organ recipients. The aim of this study is to evaluate CMV enzyme-linked immunospot (ELISPOT) assay and serology during CMV infections, their concordance and variati...

Descripción completa

Detalles Bibliográficos
Autores principales: Solidoro, Paolo, Patrucco, Filippo, Boffini, Massimo, Rinaldi, Mauro, Airoldi, Chiara, Costa, Cristina, Cavallo, Rossana, Albera, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780175/
https://www.ncbi.nlm.nih.gov/pubmed/33356914
http://dx.doi.org/10.1177/1753466620981851
_version_ 1783631462161973248
author Solidoro, Paolo
Patrucco, Filippo
Boffini, Massimo
Rinaldi, Mauro
Airoldi, Chiara
Costa, Cristina
Cavallo, Rossana
Albera, Carlo
author_facet Solidoro, Paolo
Patrucco, Filippo
Boffini, Massimo
Rinaldi, Mauro
Airoldi, Chiara
Costa, Cristina
Cavallo, Rossana
Albera, Carlo
author_sort Solidoro, Paolo
collection PubMed
description BACKGROUND: Immune responses, both cellular and humoral, against cytomegalovirus (CMV) are used to predict CMV manifestations in solid organ recipients. The aim of this study is to evaluate CMV enzyme-linked immunospot (ELISPOT) assay and serology during CMV infections, their concordance and variations after lung transplantation (LTx). METHODS: We retrospectively analysed in one year the follow-up data of 43 patients receiving combined CMV prophylaxis with antiviral agents and CMV-specific immunoglobulin G (IgG). CMV infections were investigated by using molecular analyses on both 167 bronchoalveolar lavage and biopsy specimens and 1134 blood samples. Cellular CMV immunity was assessed with specific ELISPOT whereas the humoral one was assessed by quantifying specific immunoglobulins. RESULTS: At the first month after LTx the majority of patients were ELISPOT responders (52.3%) and 30.9% were non-responders. ELISPOT responders had a lower incidence of CMV viremia (p = 0.047), whereas neither effects on CMV pulmonary asymptomatic infection nor on acute rejection were observed. Responders had a higher CMV IgG titre (p < 0.0001) in particular at the first month after LTx (p = 0.0001). Concordance among CMV ELISPOT assay and IgG levels was moderate (Cohen’s K 0.524), with an agreement of 89.8%. All ELISPOT responders maintained their status and almost all non-responders became responders during follow-up (92.3%); the percentage of IgG seropositive subjects increased from 74.4% at the first month of follow-up to 97.4% after 1 year. CONCLUSIONS: Despite a moderate concordance with serology, ELISPOT response predicted a lower incidence of CMV viremia in LTx patients; no effects were reported on pulmonary clinical manifestations nor on acute rejection. The ELISPOT response as well as serology changed during the follow-up, not only after first CMV contact. The reviews of this paper are available via the supplemental material section.
format Online
Article
Text
id pubmed-7780175
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77801752021-01-13 Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice Solidoro, Paolo Patrucco, Filippo Boffini, Massimo Rinaldi, Mauro Airoldi, Chiara Costa, Cristina Cavallo, Rossana Albera, Carlo Ther Adv Respir Dis Original Research BACKGROUND: Immune responses, both cellular and humoral, against cytomegalovirus (CMV) are used to predict CMV manifestations in solid organ recipients. The aim of this study is to evaluate CMV enzyme-linked immunospot (ELISPOT) assay and serology during CMV infections, their concordance and variations after lung transplantation (LTx). METHODS: We retrospectively analysed in one year the follow-up data of 43 patients receiving combined CMV prophylaxis with antiviral agents and CMV-specific immunoglobulin G (IgG). CMV infections were investigated by using molecular analyses on both 167 bronchoalveolar lavage and biopsy specimens and 1134 blood samples. Cellular CMV immunity was assessed with specific ELISPOT whereas the humoral one was assessed by quantifying specific immunoglobulins. RESULTS: At the first month after LTx the majority of patients were ELISPOT responders (52.3%) and 30.9% were non-responders. ELISPOT responders had a lower incidence of CMV viremia (p = 0.047), whereas neither effects on CMV pulmonary asymptomatic infection nor on acute rejection were observed. Responders had a higher CMV IgG titre (p < 0.0001) in particular at the first month after LTx (p = 0.0001). Concordance among CMV ELISPOT assay and IgG levels was moderate (Cohen’s K 0.524), with an agreement of 89.8%. All ELISPOT responders maintained their status and almost all non-responders became responders during follow-up (92.3%); the percentage of IgG seropositive subjects increased from 74.4% at the first month of follow-up to 97.4% after 1 year. CONCLUSIONS: Despite a moderate concordance with serology, ELISPOT response predicted a lower incidence of CMV viremia in LTx patients; no effects were reported on pulmonary clinical manifestations nor on acute rejection. The ELISPOT response as well as serology changed during the follow-up, not only after first CMV contact. The reviews of this paper are available via the supplemental material section. SAGE Publications 2020-12-27 /pmc/articles/PMC7780175/ /pubmed/33356914 http://dx.doi.org/10.1177/1753466620981851 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Solidoro, Paolo
Patrucco, Filippo
Boffini, Massimo
Rinaldi, Mauro
Airoldi, Chiara
Costa, Cristina
Cavallo, Rossana
Albera, Carlo
Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice
title Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice
title_full Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice
title_fullStr Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice
title_full_unstemmed Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice
title_short Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice
title_sort cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780175/
https://www.ncbi.nlm.nih.gov/pubmed/33356914
http://dx.doi.org/10.1177/1753466620981851
work_keys_str_mv AT solidoropaolo cellularandhumoralcytomegalovirusimmunitychangesinoneyearcombinedprophylaxisafterlungtransplantationsuggestionsfromandforclinicalpractice
AT patruccofilippo cellularandhumoralcytomegalovirusimmunitychangesinoneyearcombinedprophylaxisafterlungtransplantationsuggestionsfromandforclinicalpractice
AT boffinimassimo cellularandhumoralcytomegalovirusimmunitychangesinoneyearcombinedprophylaxisafterlungtransplantationsuggestionsfromandforclinicalpractice
AT rinaldimauro cellularandhumoralcytomegalovirusimmunitychangesinoneyearcombinedprophylaxisafterlungtransplantationsuggestionsfromandforclinicalpractice
AT airoldichiara cellularandhumoralcytomegalovirusimmunitychangesinoneyearcombinedprophylaxisafterlungtransplantationsuggestionsfromandforclinicalpractice
AT costacristina cellularandhumoralcytomegalovirusimmunitychangesinoneyearcombinedprophylaxisafterlungtransplantationsuggestionsfromandforclinicalpractice
AT cavallorossana cellularandhumoralcytomegalovirusimmunitychangesinoneyearcombinedprophylaxisafterlungtransplantationsuggestionsfromandforclinicalpractice
AT alberacarlo cellularandhumoralcytomegalovirusimmunitychangesinoneyearcombinedprophylaxisafterlungtransplantationsuggestionsfromandforclinicalpractice